Breaking News

WuXi AppTec Wuhan Site Resumes Ops

The Wuhan facility provides discovery chemistry services and will ramp up operations in the coming days and weeks

By: Kristin Brooks

Managing Editor, Contract Pharma

WuXi AppTec’s Wuhan site has resumed operations, in compliance with local regulations and global COVID-19 health and safety guidelines. The Wuhan facility provides discovery chemistry services, and will ramp up operations in the coming days and weeks. With this site’s re-opening, WuXi AppTec has now resumed operations at all facilities in China.  

Prior to the Wuhan site re-opening, WuXi AppTec leveraged its global site network and temporarily transferred operations to other sites to continue to support customers’ projects.

“We are working with our employees and suppliers to reach steady state operations at our Wuhan site as soon as possible,” said Steve Yang, Executive Vice President and Chief Business Officer of WuXi AppTec. “We value our customers’ contributions to the healthcare field, and put them first by providing timely and world-class quality service and continue to do the right thing for patients – a goal that WuXi AppTec has pursued since its founding.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters